Latest & greatest articles for heart failure

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heart failure or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on heart failure and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for heart failure

1. Baroreflex Activation Therapy in Patients With Heart Failure With Reduced Ejection Fraction Full Text available with Trip Pro

Baroreflex Activation Therapy in Patients With Heart Failure With Reduced Ejection Fraction Baroreflex Activation Therapy in Patients With Heart Failure With Reduced Ejection Fraction - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get the latest public health information from (...) Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation J Am Coll Cardiol Actions . 2020 Jul 7;76(1):1-13. doi: 10.1016/j.jacc.2020.05.015. Baroreflex Activation Therapy in Patients With Heart Failure With Reduced Ejection Fraction , , , , , , Affiliations Expand Affiliations 1 Medical University of South

2020 EvidenceUpdates

2. CCS Heart Failure Guidelines Update: Focus on FMR, SGLT2 Inhibitors, ARNI in HFpEF, and Amyloidosis Full Text available with Trip Pro

on selected topics of high clinical relevance for health care providers who treat patients with heart failure (HF), on the basis of clinical trials published after 2017. Our objective was to review the evidence, and provide recommendations and practical tips regarding the management of candidates for the following HF therapies: (1) transcatheter mitral valve repair in HF with reduced ejection fraction; (2) a novel treatment for transthyretin amyloidosis or transthyretin cardiac amyloidosis; (3 (...) CCS Heart Failure Guidelines Update: Focus on FMR, SGLT2 Inhibitors, ARNI in HFpEF, and Amyloidosis CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis - Canadian Journal of Cardiology Go search , P159-169, February 01, 2020 Powered By Mendeley CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis

2020 Canadian Cardiovascular Society

3. Electrical stimulation to improve muscle strength in chronic respiratory conditions, chronic heart failure and chronic kidney disease

commentary was sought but none was received. Committee comments Committee comments 3.5 The committee noted that the procedure may be contraindicated in patients who have an electronic implant (such as a cardiac pacemaker or defibrillator). Electrical stimulation to improve muscle strength in chronic respiratory conditions, chronic heart failure and chronic kidney disease (IPG677) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights (...) Electrical stimulation to improve muscle strength in chronic respiratory conditions, chronic heart failure and chronic kidney disease Electrical stimulation to improve muscle strength in chronic respiratory conditions, chronic heart failure and chronic kidney disease Interventional procedures guidance Published: 5 August 2020 www.nice.org.uk/guidance/ipg677 Your responsibility Your responsibility This guidance represents the view of NICE, arrived at after careful consideration of the evidence

2020 National Institute for Health and Clinical Excellence - Interventional Procedures

4. Effects of self-management interventions on heart failure: Systematic review and meta-analysis of randomized controlled trials

Effects of self-management interventions on heart failure: Systematic review and meta-analysis of randomized controlled trials Effects of self-management interventions on heart failure: Systematic review and meta-analysis of randomized controlled trials - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging (...) ? Report format: Send at most: Send even when there aren't any new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Review Int J Nurs Stud Actions . 2020 Jun 16;110:103689. doi: 10.1016/j.ijnurstu.2020.103689. Online ahead of print. Effects of self-management interventions on heart failure

2020 EvidenceUpdates

5. Meta-Analysis Comparing Outcomes of Therapies for Patients With Central Sleep Apnea and Heart Failure With Reduced Ejection Fraction Full Text available with Trip Pro

Meta-Analysis Comparing Outcomes of Therapies for Patients With Central Sleep Apnea and Heart Failure With Reduced Ejection Fraction Meta-Analysis Comparing Outcomes of Therapies for Patients With Central Sleep Apnea and Heart Failure With Reduced Ejection Fraction - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes (...) of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Am J Cardiol Actions . 2020 Jul 15;127:73-83. doi: 10.1016/j.amjcard.2020.04.011. Epub 2020 Apr 24. Meta-Analysis Comparing Outcomes of Therapies for Patients With Central Sleep Apnea and Heart Failure With Reduced Ejection Fraction , , , , Affiliations Expand Affiliations 1 Medical Device Consultants, Ridgewood, New Jersey. Electronic address: meddevconsultant@aol.com. 2 Division

2020 EvidenceUpdates

6. Net clinical benefit of antithrombotic therapy in patients with heart failure and sinus rhythm: A network meta-analysis from 5 clinical trials

Net clinical benefit of antithrombotic therapy in patients with heart failure and sinus rhythm: A network meta-analysis from 5 clinical trials Net clinical benefit of antithrombotic therapy in patients with heart failure and sinus rhythm: A network meta-analysis from 5 clinical trials - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable (...) Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Review Thromb Res Actions . 2020 Jun;190:122-128. doi: 10.1016/j.thromres.2020.04.017. Epub 2020 Apr 18. Net clinical benefit of antithrombotic therapy in patients with heart failure and sinus rhythm: A network meta-analysis from 5 clinical trials , , , , , , , Affiliations Expand Affiliations 1 Department of Pharmacy, Renji Hospital, School of Medicine

2020 EvidenceUpdates

7. Lung ultrasound-guided therapy reduces acute decompensation events in chronic heart failure

Lung ultrasound-guided therapy reduces acute decompensation events in chronic heart failure Lung ultrasound-guided therapy reduces acute decompensation events in chronic heart failure - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National Library of Medicine National Center for Biotechnology (...) Actions Cite Share Permalink Copy Page navigation Heart Actions . 2020 Jun 22;heartjnl-2019-316429. doi: 10.1136/heartjnl-2019-316429. Online ahead of print. Lung ultrasound-guided therapy reduces acute decompensation events in chronic heart failure , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Cardiovascular Imaging Unit, San Raffaele Scientific Institute, Milan, Italy claudia.marini@outlook.com. 2 Heart Failure Clinic, Clinical Cardiology, San Raffaele Scientific Institute, Milan

2020 EvidenceUpdates

8. Family Caregiving for Individuals With Heart Failure: A Scientific Statement From the American Heart Association

Family Caregiving for Individuals With Heart Failure: A Scientific Statement From the American Heart Association Family Caregiving for Individuals With Heart Failure: A Scientific Statement From the American Heart Association | Circulation Search Search Hello Guest! Login to your account Email Password Keep me logged in Search Search June 2020 May 2020 April 2020 March 2020 February 2020 January 2020 This site uses cookies. By continuing to browse this site you are agreeing to our use (...) of cookies. Free Access article Share on Jump to Free Access article Family Caregiving for Individuals With Heart Failure: A Scientific Statement From the American Heart Association , PhD, RN, FAHA, Chair , DNP, ANP, FAHA, Vice Chair , PhD, RN , PhD, RN , MD, MS , PhD, RN, FAHA , MSHI, RN-BC , PhD, RPh, FAHA , PhD , PhD Lisa Kitko , Colleen K. McIlvennan , Julie T. Bidwell , J. Nicholas Dionne-Odom , Shannon M. Dunlay , Lisa M. Lewis , Ginny Meadows , Elisabeth L.P. Sattler , Richard Schulz , Anna

2020 American Heart Association

9. Addressing Social Determinants of Health in the Care of Patients With Heart Failure: A Scientific Statement From the American Heart Association

Addressing Social Determinants of Health in the Care of Patients With Heart Failure: A Scientific Statement From the American Heart Association Addressing Social Determinants of Health in the Care of Patients With Heart Failure: A Scientific Statement From the American Heart Association | Circulation Search Search Hello Guest! Login to your account Email Password Keep me logged in Search Search June 2020 May 2020 April 2020 March 2020 February 2020 January 2020 This site uses cookies (...) . By continuing to browse this site you are agreeing to our use of cookies. Free Access article Share on Jump to Free Access article Addressing Social Determinants of Health in the Care of Patients With Heart Failure: A Scientific Statement From the American Heart Association , PhD, RN, FAHA, Chair , PhD, RN, Vice Chair , MD, MSPH , PhD, NP, FAHA , MD, MPH , PhD, RN, FAHA , PhD, MSN, FAHA , PhD, RN, FAHA , ANP, CNS, FAHA , PhD, MBA, RN Connie White-Williams , Laura P. Rossi , Vera A. Bittner , Andrea Driscoll

2020 American Heart Association

10. Personalized Rate-Response Programming Improves Exercise Tolerance After 6 Months in People With Cardiac Implantable Electronic Devices and Heart Failure: A Phase II Study

Personalized Rate-Response Programming Improves Exercise Tolerance After 6 Months in People With Cardiac Implantable Electronic Devices and Heart Failure: A Phase II Study Personalized Rate-Response Programming Improves Exercise Tolerance After 6 Months in People With Cardiac Implantable Electronic Devices and Heart Failure: A Phase II Study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History (...) a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Circulation Actions . 2020 May 26;141(21):1693-1703. doi: 10.1161/CIRCULATIONAHA.119.045066. Epub 2020 Apr 17. Personalized Rate-Response Programming Improves Exercise Tolerance After 6 Months in People With Cardiac Implantable Electronic Devices and Heart Failure: A Phase II Study

2020 EvidenceUpdates

11. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. (Abstract)

Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Three drug classes (mineralocorticoid receptor antagonists [MRAs], angiotensin receptor-neprilysin inhibitors [ARNIs], and sodium/glucose cotransporter 2 [SGLT2] inhibitors) reduce mortality in patients with heart failure with reduced ejection fraction (HFrEF) beyond conventional (...) HFrEF.In this cross-trial analysis, we estimated treatment effects of comprehensive disease-modifying pharmacological therapy (ARNI, β blocker, MRA, and SGLT2 inhibitor) versus conventional therapy (ACE inhibitor or ARB and β blocker) in patients with chronic HFrEF by making indirect comparisons of three pivotal trials, EMPHASIS-HF (n=2737), PARADIGM-HF (n=8399), and DAPA-HF (n=4744). Our primary endpoint was a composite of cardiovascular death or first hospital admission for heart failure; we also

2020 Lancet

12. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. (Abstract)

Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. The effect of vericiguat, a novel oral soluble guanylate cyclase stimulator, in patients with heart failure and reduced ejection fraction who had recently been hospitalized or had received intravenous diuretic therapy is unclear.In this phase 3, randomized, double-blind, placebo-controlled trial, we assigned 5050 patients with chronic heart failure (New York Heart Association class II, III, or IV) and an ejection fraction (...) of 691 patients (27.4%) in the vericiguat group and 747 patients (29.6%) in the placebo group were hospitalized for heart failure (hazard ratio, 0.90; 95% CI, 0.81 to 1.00). Death from cardiovascular causes occurred in 414 patients (16.4%) in the vericiguat group and in 441 patients (17.5%) in the placebo group (hazard ratio, 0.93; 95% CI, 0.81 to 1.06). The composite of death from any cause or hospitalization for heart failure occurred in 957 patients (37.9%) in the vericiguat group and in 1032

2020 NEJM

13. Position Statement on COVID-19 and Acute Heart Failure: screening the critically ill

of heart failure, whilst nearly 60% had elevated biochemical markers consistent with acute cardiac injury [4]. In two separate cohort studies from Wuhan [3,5], the proportion of COVID-19 patients with evidence of cardiac injury [as defined by elevated levels of high sensitivity troponin (hsTn) with or without other biochemical markers] ranged from 20 to 28%. In both studies, patients with elevated hsTn were older and more likely to have a range of cardiovascular comorbidities including hypertension (...) , diabetes, coronary artery disease and prior heart failure. In both studies, an elevated hsTn was associated with a marked increase in mortality: 50-60% in those with an elevated hsTn compared with a mortality rate of 5-10% for those who had a normal hsTn during hospitalisation. In addition, COVID-19 patients with elevated hsTn during admission experienced higher rates of acute respiratory distress syndrome (ARDS) necessitating higher rates of non-invasive and invasive ventilation, acute renal failure

2020 Cardiac Society of Australia and New Zealand

14. Association of Intensive Lifestyle Intervention, Fitness, and Body Mass Index With Risk of Heart Failure in Overweight or Obese Adults With Type 2 Diabetes Mellitus: An Analysis From the Look AHEAD Trial

Association of Intensive Lifestyle Intervention, Fitness, and Body Mass Index With Risk of Heart Failure in Overweight or Obese Adults With Type 2 Diabetes Mellitus: An Analysis From the Look AHEAD Trial Association of Intensive Lifestyle Intervention, Fitness, and Body Mass Index With Risk of Heart Failure in Overweight or Obese Adults With Type 2 Diabetes Mellitus: An Analysis From the Look AHEAD Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage (...) any new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Actions Cite Share Permalink Copy Page navigation Circulation Actions . 2020 Apr 21;141(16):1295-1306. doi: 10.1161/CIRCULATIONAHA.119.044865. Epub 2020 Mar 5. Association of Intensive Lifestyle Intervention, Fitness, and Body Mass Index With Risk of Heart Failure in Overweight or Obese Adults With Type 2 Diabetes Mellitus: An Analysis From the Look AHEAD Trial

2020 EvidenceUpdates

15. Management of the Hospitalized COVID-19 Patient With Acute Cardiomyopathy or Heart Failure

L. How to balance acute myocardial infarction and COVID-19: the protocols from Sichuan Provincial People's Hospital. Intensive Care Med 2020;March 11:[Epub ahead of print]. Li H, Zhou Y, Zhang M, Wang H, Zhao Q, Liu J. Updated approaches against SARS-CoV-2. Antimicrob Agents Chemother 2020;March 23:[Epub ahead of print]. Share via: Clinical Topics: Keywords: Acute Coronary Syndrome, Anticoagulants, Arrhythmias, Cardiac, Cardiac Surgical Procedures, Metabolic Syndrome X, Angina, Stable, Heart (...) Management of the Hospitalized COVID-19 Patient With Acute Cardiomyopathy or Heart Failure Feature | Management of the Hospitalized COVID-19 Patient With Acute Cardiomyopathy or Heart Failure - American College of Cardiology ') Search All Types Search or Menu This article was authored by Joel D. Schilling, MD, PhD , Washington University School of Medicine, St. Louis, MO; Ashwin K. Ravichandran, MD, FACC , St. Vincent's Medical Group, Indianapolis, IN; and Stacy A. Mandras, MD, FACC , Oschner

2020 American College of Cardiology

16. Canadian Cardiovascular Society/Canadian Heart Failure Society Joint Position Statement on the Evaluation and Management of Patients With Cardiac Amyloidosis Full Text available with Trip Pro

Canadian Cardiovascular Society/Canadian Heart Failure Society Joint Position Statement on the Evaluation and Management of Patients With Cardiac Amyloidosis Canadian Cardiovascular Society/Canadian Heart Failure Society Joint Position Statement on the Evaluation and Management of Patients With Cardiac Amyloidosis - Canadian Journal of Cardiology Go search , P322-334, March 01, 2020 Powered By Mendeley Share on Canadian Cardiovascular Society/Canadian Heart Failure Society Joint Position (...) Columbia, Canada Sean A. Virani Affiliations University of British Columbia, Vancouver, British Columbia, Canada Shelley Zieroth Affiliations University of Manitoba, Winnipeg, Manitoba, Canada DOI: Abstract Cardiac amyloidosis is an under-recognized and potentially fatal cause of heart failure and other cardiovascular manifestations. It is caused by deposition of misfolded precursor proteins as fibrillary amyloid deposits in cardiac tissues. The two primary subtypes of systemic amyloidosis causing

2020 Canadian Cardiovascular Society

17. Is it COVID-19 or Is it Heart Failure? Management of Ambulatory Heart Failure Patients

Is it COVID-19 or Is it Heart Failure? Management of Ambulatory Heart Failure Patients GUIDANCE FROM THE CCS COVID-19 RAPID RESPONSE TEAM Is it COVID-19 or Is it Heart Failure? Management of Ambulatory Heart Failure Patients Introduction To preserve healthcare resources and prevent vulnerable patients from being unnecessarily exposed to healthcare facilities and the Emergency Department (ED), healthcare practitioners are screening patients via virtual assessment (phone, telehealth or regionally (...) available platforms), in order to determine the appropriate diagnostic and treatment approach. The following is simple, practical guidance on patient evaluation and use of laboratory testing. Symptom evaluation The following tool is designed to guide your clinical reasoning to differentiate the likely etiology of symptoms for a patient with known heart failure (HF). It has not been validated, and the final determination must be made using clinical judgement. In cases of uncertainty, patients should

2020 Canadian Cardiovascular Society

18. OUTSMART HF: A Randomized Controlled Trial of Routine Versus Selective Cardiac Magnetic Resonance for Patients With Nonischemic Heart Failure (IMAGE-HF 1B)

OUTSMART HF: A Randomized Controlled Trial of Routine Versus Selective Cardiac Magnetic Resonance for Patients With Nonischemic Heart Failure (IMAGE-HF 1B) OUTSMART HF: A Randomized Controlled Trial of Routine Versus Selective Cardiac Magnetic Resonance for Patients With Nonischemic Heart Failure (IMAGE-HF 1B) - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard (...) in email: Save Cancel Create a file for external citation management software Create file Cancel Actions Cite Share Permalink Copy Page navigation Circulation Actions . 2020 Mar 10;141(10):818-827. doi: 10.1161/CIRCULATIONAHA.119.043964. Epub 2020 Jan 8. OUTSMART HF: A Randomized Controlled Trial of Routine Versus Selective Cardiac Magnetic Resonance for Patients With Nonischemic Heart Failure (IMAGE-HF 1B) , , , , , , , , , , , , , , , , , , , Collaborators, Affiliations Expand Collaborators IMAGE-HF

2020 EvidenceUpdates

19. Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. (Abstract)

Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. Additional treatments are needed for heart failure with reduced ejection fraction (HFrEF). Sodium-glucose cotransporter 2 (SGLT2) inhibitors may be an effective treatment for patients with HFrEF, even those without diabetes.To evaluate the effects of dapagliflozin in patients with HFrEF with and without diabetes.Exploratory analysis of a phase 3 randomized trial (...) conducted at 410 sites in 20 countries. Patients with New York Heart Association classification II to IV with an ejection fraction less than or equal to 40% and elevated plasma N-terminal pro B-type natriuretic peptide were enrolled between February 15, 2017, and August 17, 2018, with final follow-up on June 6, 2019.Addition of once-daily 10 mg of dapagliflozin or placebo to recommended therapy.The primary outcome was the composite of an episode of worsening heart failure or cardiovascular death

2020 JAMA

20. 2020 ACC/HFSA/ISHLT Lifelong Learning Statement for Advanced Heart Failure and Transplant Cardiology Specialists

of selected AHFTC specialists on the basis of background, specialized knowledge, skills, experience, and practice focus (right column). This distinction is particularly relevant to the patient care competencies and recognizes diversity in the focus of practice of AHFTC specialists. Some physicians may specialize in a particular aspect of AHFTC, such as mechanical circulatory support or cardiac transplantation, while others may adopt a practice focused on patients with chronic heart failure with a lesser (...) , there is a growing subspecialization career focus within AHFTC. Specifically, some practitioners limit the scope of their clinical activity to treating patients with advanced heart failure, including those who undergo implantation of a durable ventricular assist device or cardiac transplantation, while others focus on disease management of patients with less advanced heart failure. Thus, although maintenance of some AHFTC competencies is an expectation for all clinical AHFTC specialists, the maintenance

2020 International Society for Heart and Lung Transplantation